104 related articles for article (PubMed ID: 20172322)
21. Rituximab in highly sensitized kidney transplant recipients.
Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
[TBL] [Abstract][Full Text] [Related]
22. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
[TBL] [Abstract][Full Text] [Related]
23. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
24. Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors.
Mittal SK; Sharma RK; Gupta A; Naik S
Transplantation; 2009 Aug; 88(3):435-41. PubMed ID: 19667950
[TBL] [Abstract][Full Text] [Related]
25. [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].
Rufino Hernández JM; Cabello Moya E; González-Posada JM; Hernández Marrero D; Pérez Tamajón L; Marrero Miranda D; García Rebollo S; Martín Urcuyo B; Rodríguez Hernández A; Franco Maside A; Barrios del Pino Y; Rodríguez Rodríguez R; Maceira Cruz B; Torres Ramírez A; Salido Ruiz E
Nefrologia; 2010; 30(2):252-7. PubMed ID: 20098463
[TBL] [Abstract][Full Text] [Related]
26. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.
McCurry KR; Iacono A; Zeevi A; Yousem S; Girnita A; Husain S; Zaldonis D; Johnson B; Hattler BG; Starzl TE
J Thorac Cardiovasc Surg; 2005 Aug; 130(2):528-37. PubMed ID: 16077423
[TBL] [Abstract][Full Text] [Related]
27. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
28. [Regulatory T cells in kidney transplant recipients].
Libetta C; Portalupi V; Margiotta E; Sepe V; Canevari M; Meloni F; Morosini M; Dal Canton A
G Ital Nefrol; 2009; 26 Suppl 45():S54-7. PubMed ID: 19382095
[TBL] [Abstract][Full Text] [Related]
29. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
Knight RJ; Kerman RH; Podder H; Katz SM; Van Buren CT; Kahan BD
Transplant Proc; 2005 Mar; 37(2):1280-2. PubMed ID: 15848695
[TBL] [Abstract][Full Text] [Related]
30. Clinical rejection and persistent immune regulation in kidney transplant patients.
Hendrikx TK; Klepper M; Ijzermans J; Weimar W; Baan CC
Transpl Immunol; 2009 Jul; 21(3):129-35. PubMed ID: 19398001
[TBL] [Abstract][Full Text] [Related]
31. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
Tan HP; Kaczorowski D; Basu A; McCauley J; Marcos A; Donaldson J; Unruh M; Randhawa P; Zeevi A; Shapiro R
Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
[TBL] [Abstract][Full Text] [Related]
32. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
Tan J; Yang S; Wu W
Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
[TBL] [Abstract][Full Text] [Related]
33. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
Basu A; Ramkumar M; Tan HP; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R
Transplant Proc; 2005 Mar; 37(2):923-6. PubMed ID: 15848576
[TBL] [Abstract][Full Text] [Related]
34. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
35. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S
Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
[TBL] [Abstract][Full Text] [Related]
36. Rituximab induction therapy in highly sensitized kidney transplant recipients.
Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
[TBL] [Abstract][Full Text] [Related]
37. Kidney transplantation achievements in Mongolia.
Jambaljav L; Nyamsuren D; Byambadash B; Ganbold L
Transplant Proc; 2010 Apr; 42(3):791-2. PubMed ID: 20430173
[TBL] [Abstract][Full Text] [Related]
38. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies.
Opelz G;
Lancet; 2005 Apr 30-May 6; 365(9470):1570-6. PubMed ID: 15866311
[TBL] [Abstract][Full Text] [Related]
39. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
[TBL] [Abstract][Full Text] [Related]
40. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction.
Cai J; Terasaki PI; Bloom DD; Torrealba JR; Friedl A; Sollinger HW; Knechtle SJ
Transplantation; 2004 Sep; 78(6):919-24. PubMed ID: 15385814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
